Tumefactive Multiple Sclerosis Lesions under Fingolimod Treatment
Neurol 79:2000-2002,1942, Visser, F.,et al, 2012
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Treatment of Early Onset Multiple Sclerosis With Subcutaneous Interferon Beta-1a
Neurol 64:888-890, 778, Pohl,D., et al, 2005
Polyneuropathy Associated with Interferon Beta Treatment in Patients with Multiple Sclerosis
Neurol 65:456-458, Ekstein,D.,et al, 2005
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Mitoxantrone Treatment of Multiple Sclerosis
Neurol 63(Suppl 6):S28-S32, Cohen,B.A. &Mikol,D.D., 2004
Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002
Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999
Effect of Interferon-B on Blood-Brain Barrier Disrupt Demonst by Contrast MRI in Relapsing-Remitting MS
Ann Neurol 37:611-619, Stone,L.A.,et al, 1995
Chronic Systemic High-Dose Recombinant Interferon Alfa-2a Reduces Exacerbation Rate & MRI Signs in MS
Neurol 44:406-413, Durelli,L.,et al, 1994
Efficacy & Toxicity of Cyclosporine in Chronic Progressive Multiple Sclerosis:A Randomized Clinical Trial
M. S. Study Group, Ann Neurol 27:591-605, 5890., , 1990
Randomised Double Blind Controlled Trial of Cyclosporin in Multiple Sclerosis
JNNP 52:559-565, Rudge,P.,et al, 1989
Important Advances in Clinical Medicine
West J Med 123:128, Mosier,J.M.,et al, 1975